According to the research report titled ‘Asia Pacific In-vitro Colorectal Cancer Screening Tests Market Share By Test Type, Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 – 2026’ available with Market Study Report, Asia-Pacific in-vitro colorectal cancer screening tests market is expected to surpass a valuation of USD 230 million by the year 2026.
 

Factors such as growing prevalence of colorectal cancer as well as lifestyle-related genetic disorders along with surging demand for safe and premium endoscopy facilities are propelling the growth of Asia-Pacific in-vitro colorectal cancer screening tests market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2609887/
 

Furthermore, favorable government initiatives as well as investments towards the early detection of colorectal cancer are stimulating the overall market outlook. On the contrary, lack of reimbursement in emerging nations is expected to hamper the expansion of the market throughout the analysis timeframe.
 

Based on test type, Asia-Pacific in-vitro colorectal cancer screening tests market from the FOBT (fecal occult blood test) segment was worth around USD 96 million in the year 2019 and is anticipated to witness significant growth through 2026. High affordability and growing popularity due to ease of operation, along with increasing sensitivity as well as specificity of stool-based tests are fostering the growth of the segment.
 

As per the country-level analysis, Japan is estimated to emerge as a major revenue generator for Asia-Pacific in-vitro colorectal cancer screening tests market during 2020-2026. Factors such as growing awareness regarding early detection of the cancer, rising demand for FOBT as well as OC colorectal cancer screening tests, and increasing investments towards research and development in colorectal cancer screening are positively swaying the market dynamics in the country.
 

The companies that have an authoritative status in Asia-Pacific in-vitro colorectal cancer screening tests market are Sysmex Corporation, Siemens Healthineers AG, Roche Molecular System, Inc., R-Biopharm AG, Randox Laboratories Ltd., Kyowa Kirin Co., Ltd. (Kyowa Medex Co., Ltd.), Merck Millipore (Merck Group), Eiken Chemical Co. Ltd., Beckman Coulter, Inc., and Abbott Laboratories.